PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 635-642

  Dredge, K ^a   Hammond, E ^a   Handley, P ^a   Gonda, T J ^b   Smith, M T ^b   Vincent, C ^c   Brandt, R ^c   Ferro, V ^a,b   Bytheway, I ^a  

^a Progen Pharmaceuticals Limited   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Vivo Pharm Pty Ltd   (Australia)

Author keywords

angiogenesis; anti metastatic; anti tumour; heparan sulfate; heparanase

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GEFITINIB; HEPARANASE; PG 545; SORAFENIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COLON CANCER; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HEAD AND NECK CANCER; ISOTOPE LABELING; LIVER CANCER; LOADING DRUG DOSE; LUNG CANCER; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GLUCURONIDASE; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS; SAPONINS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951676056     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.11     Document Type: Article

References (34)

1. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277(19): 3890-3903
2. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG (2006) A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12: 5471-5480 (Pubitemid 44497263)
3. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936 (Pubitemid 43093958)
4. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309 (Pubitemid 41443415)
5. Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL (2008) Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res 17: 183-189
6. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, Ferro V, Bytheway I (2010) The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 28: 276-283
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239
8. Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369(9574): 1742-1757 (Pubitemid 46755391)
9. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286 (Pubitemid 46505878)
10. Gandhi NS, Mancera RL (2010) Heparin/heparan sulphate-based drugs. Drug Discov Today 15(23-24): 1058-1069
11. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, Schirrmacher V, Mitrani E, Vlodavsky I (2002) Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99: 10031-10036 (Pubitemid 34831167)
12. Hammond E, Bytheway I, Ferro V (2006) Heparanase as a target for anticancer therapeutics: new developments and future prospects. In New Developments in Therapeutic Glycomics, Delehedde M (ed), pp 251-282. Research Signpost: Kerala
13. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, Chiu FCK, Shackleford DM, Charman SA, Charman WN, Harenberg J, Gonda TJ, Ferro V (2010) Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem 53(4): 1686-1699
14. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4(4): 641-649 (Pubitemid 40601846)
15. Karoli T, Liu L, Fairweather JK, Hammond E, Li CP, Cochran S, Bergefall K, Trybala E, Addison RS, Ferro V (2005) Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 48: 8229-8236 (Pubitemid 43032531)
16. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50: 958-968
17. Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3): 167-170
18. Marchetti D, Reiland J, Erwin B, Roy M (2003) Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 104: 167-174 (Pubitemid 36249791)
19. McCarty MF, Baker CH, Bucana CD, Fidler IJ (2002) Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 21: 5-10
20. McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14 (Pubitemid 46675998)
21. Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y (2008) Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res 14: 6055-6061
22. Nakajima M, Irimura T, Nicolson GL (1988) Heparanases and tumor metastasis. J Cell Biochem 36: 157-167
23. Norrby K (2006) Low-molecular-weight heparins and angiogenesis. APMIS 114: 79-102 (Pubitemid 43356919)
24. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231
25. Paw HGW (2006) Loading dose. In Handbook of Drugs in Intensive Care: An A-Z Guide, pp 190. 3rd Ed. HGW Paw and G Park (editors). Cambridge University Press, Cambridge, UK
26. Rivera RS, Nagatsuka H, Siar CH, Gunduz M, Tsujigiwa H, Han PP, Katase N, Tamamura R, Ng KH, Naomoto Y, Nakajima M, Nagai N (2008) Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep 19: 657-661 (Pubitemid 351330432)
27. Sparano JA, Gray R, Giantonio B, O'Dwyer P, Comis RL (2004) Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res 10: 1206-1211 (Pubitemid 38365208)
28. Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR (2009) Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 15: 4529
29. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15: 177-186 (Pubitemid 26236115)
30. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, Peretz T (1994) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14: 290-302
31. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109 (Pubitemid 39331023)
32. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N (2006) Heparanase induces vascular endothelial growth factor expres-sion: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66: 1455-1463 (Pubitemid 43259926)
33. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424 (Pubitemid 28197463)
34. Zheng LD, Tong QS, Tang ST, Du ZY, Liu Y, Jiang GS, Cai JB (2009) Expression and clinical significance of heparanase in neuroblastoma. World J Pediatr 5: 206-210